Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight

American Journal of Hematology

Volumn 88, Issue 10, 2013, Pages 906-909

  Wenzell, Candice M ^a   Gallagher, Erika M ^a   Earl, Marc ^a   Yeh, Jun Yen ^a   Kusick, Karissa N ^a   Advani, Anjali S ^b   Kalaycio, Matt E ^b   Mukherjee, Sudipto ^b   Tiu, Ramon V ^b   Maciejewski, Jaroslaw P ^b   Sekeres, Mikkael A ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; BODY MASS; BODY SURFACE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CYTOGENETICS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMAN; INCIDENCE; INDUCTION CHEMOTHERAPY; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL; OBESITY; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; THROMBOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84884707447     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23530     Document Type: Article

References (19)

1. Ratain MJ. Body-surface area as a basis for dosing of anticancer agents: Science, myth, or habit? J Clin Oncol 1998;16:2297-2298.
2. Abdah-Bortnyak R, Tsalic M, Haim N. Actual body weight for determining doses of chemotherapy in obese cancer patients. Med Oncol 2003;20:363-367.
3. Lind MJ, Margison JM, Cerney T, et al. Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmcol 1989;25:139-142.
4. Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol 1988;6:1321-1327.
5. Powis G, Reece P, Ahmann DL, Ingle JN. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 1987;20:219-222.
6. Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 2007;25:4707-4713.
7. Hunter RJ, Navo MA, Thaker PH, et al. Dosing chemotherapy in obese patients: Actual versus assigned body surface area. Cancer Treat Rev 2009;35:69-78.
8. Cheymol G. Effects of obesity on pharmacokinetics: Implications for drug therapy. Clin Pharmacokinet 2000;39:215-231.
9. Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012;30:1553-1561.
10. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-4336.
11. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report. National Institutes of Health. Obes Res 1998;6:51S-209S.
12. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-4649.
13. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009-2010. NCHS data brief, no 82. Available from URL: http://www.cdc.gov/nchs/data/databriefs/db82.pdf [accessed September 30, 2012].
14. Lyman GH. Weight-based chemotherapy dosing in obese patients with cancer: Back to the Future. J Oncol Pract 2012;8:e62-e64.
15. Lyman, G. Commentary: Chemotherapy dosing in obese patients with cancer-The need for evidence-based clinical practice guidelines. J Oncol Pract 2011;7:17-18.
16. Lin A, Othus M, McQuary A, et al. Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. Leuk Lymphoma 2013;54:541-546.
17. Lee HJ, Licht AS, Hyland AJ, et al. Is obesity a prognostic factor for acute myeloid leukemia outcome? Ann Hematol 2012;91:359-365.
18. Medeiros BC, Othus M, Estey EH, et al. Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. Haematologica 2012;97:1401-1404.
19. Lange BJ, Gerbing RB, Feusner J, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA 2005;293:203-211.